Objectives:

  1. Understand currently available medication for the treatment of sickle cell
  2. Learning Objective 2:Understand the role Endari has in the treatment of sickle cell
  3. Learning Objective 3:Understand the short comings of Endari
  4. Can icosapent ethyl reduce CV Risk in patients with hypertriglyceridemia?
  5. Learning Objective 2:Does icosapent ehthyl have additive benefit to statins in patients with DM or CV ds and hypertriglyceridemia.
  6. Learning Objective 3:Critical review of randomized trial
Session date: 
Monday, March 4, 2019 - 12:00pm to 1:00pm
Speaker Name: 
Drs. Nabil Abou Baker & Todd Stern
Location: 
UCMC Room L431
Chicago, IL 60637
United States
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.